Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048802 | 0.84 | AHR (0.52) | GAAPSIP1APEX1PTGDR2 | |
| SCHEMBL7948250 | 0.83 | GAA (0.44) | ALDH1A1GAAPSIP1PTGDR2POLB | |
| SCHEMBL7946206 | 0.83 | FLT1 (0.44) | ALDH1A1GAAPSIP1PTGDR2POLB | |
| SCHEMBL15960059 | 0.83 | THRB (0.51) | MAPK1ALDH1A1KMT2AMEN1THRB | |
| SCHEMBL11856294 | 0.83 | ALDH1A1 (0.47) | MAPK1ALDH1A1APEX1KMT2AMEN1 | |
| SCHEMBL585199 | 0.82 | PTGS2 (0.49) | ALDH1A1PTGDR2KMT2AMEN1 | |
| SCHEMBL9806947 | 0.82 | CA1 (0.63) | MAPK1ALDH1A1GAAPSIP1PTGDR2 | |
| SCHEMBL2393378 | 0.82 | GAA (0.42) | MAPK1ALDH1A1GAAPSIP1PTGDR2 | |
| SCHEMBL2397432 | 0.82 | ALDH1A1 (0.51) | ALDH1A1GAAPSIP1PTGDR2POLB | |
| SCHEMBL708295 | 0.82 | GAA (0.42) | ALDH1A1GAAPSIP1PTGDR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | MAPK1 1370/4885ALDH1A1 3104/4885GAA 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.